Tuberc Respir Dis Search

CLOSE


Tuberc Respir Dis > Volume 52(2); 2002 > Article
Tuberculosis and Respiratory Diseases 2002;52(2):128-136.
DOI: https://doi.org/10.4046/trd.2002.52.2.128    Published online February 1, 2002.
Pharmacokinetics of ofloxacin in Patients with Multidrug-Resistant Tuberculosis.
Seung Kyu Park, , Young Ran Yoon, , Woo Chul Lee, , Hyung Min Jun, , Ji Hong Shon, , Kyoung Ah Kim, , Ji Young Park, , Jae Gook Shin,
1Department of Chest Surgery, National Masan Tuberculosis Hospital, Korea.
2Department of Pharmacology, Inje University College of Medicine and Clinical Phamacology Center, Pusan Paik Hospital, Masan, Pusan, Korea. phyoonyr@ijnc.inje.ac.kr
Abstract
BACKGROUND
There are few studies that have reported on the pharmacokinetic(PK) disposition of fluoroquinolones in patients with multi-drug resistant tuberculosis(MDR-Tb), even though fluoroquinolones are frequentl y co-prescribed to those patients. In this study, the PK disposition of ofloxacin, a fluoroquinolone, was evaluated in patients with MDR-Tb. METHODS: Twenty patients with MDR-Tb were given 2nd line Tb drugs including ofloxacin (300mg twice a day), prothionamide, cycloserine, para-aminosalicylic acid, kanamycin, and streptomycin. The patients were grouped according to their body mass index(BMI) as an index of emaciation (group A: 18.5
Key Words: MDR-Tb, Ofloxacin, Pharmacokinetics, BMI


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2021 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2community

Close layer
prev next